Nutriband Raises $1.75 Million from Warrant Exercises to Fund AVERSA Fentanyl Development
Nutriband (NTRB) has raised $1.75 million through the exercise of its NTRBW warrants, with investors purchasing a total of 272,671 shares at $6.43 per share before their expiration on September 30. The company now holds no remaining tradeable warrants following this event. Funds from the warrant exercises will be used to support ongoing clinical development for AVERSA Fentanyl and prepare its new drug application submission to the FDA. AVERSA Fentanyl is positioned as a groundbreaking opioid patch with abuse-deterrent properties, aiming to address concerns around prescription drug misuse in the U.S. market. Nutriband estimates that peak annual sales of this product could reach between $80 million and $200 million once launched.
Tickers: $NTRB